Jay T. Flatley
Independent DirectorMr. Jay T. Flatley is Chairman of Cellanome, Inc. Mr. Flatley was Director of Cellanome, Inc. Mr. Flatley is Director of The Salk Institute For Biological STUDIES, San Diego, California. Mr. Flatley is Independent Director of Denali Therapeutics Inc. from April 2015. He is Advisor of Iif Management Company, LLC. He is Independent Director of Rivian Automotive, Inc. from May 2021. He is Director of Helix Holdings I, LLC. He is Member of Advisor of Variant Bio, Inc. He is Director of Cellanome, Inc. He is Chairman of the Board of Wellcome Leap Inc. He is Advisor of Time BioVentures. He was Chairman of Illumina, Inc. from January 01, 2020 to May 2021. He was Executive Chairman of Illumina, Inc. from July 2016 to January 01, 2020. He was employed at Illumina, Inc. from October 1999 to May 2021. He was Director of Juno Therapeutics, Inc. until March 06, 2018. He was employed at Juno Therapeutics, Inc. from May 23, 2017 to March 06, 2018. He was Chief Executive Officer, President, Acting Chief Financial Officer and Director of Molecular Dynamics, Inc. He joined the Molecular Dynamics, Inc. in August 1991. He was Independent Director of Coherent, Inc. from 2011 to July 01, 2022. He was employed at Coherent, Inc. from 2011 to July 01, 2022. He was Director of Bruker AXS, Inc. He joined the Bruker AXS, Inc. in November 2000. He was Director of GenVault Corporation. He was Chief Executive Officer of Illumina Inc from 1999 until 2016. and President of Illumina Inc of CyVera Corporation. He oversaw the company’s expansion from microarrays into next-generation sequencing. He was Director of Helixis, Inc. He joined the Helixis, Inc. in February 2009. He was Chairman of Zymergen Inc. from October 18, 2022 to October 18, 2022. He was Chairman & Acting CEO of Zymergen Inc. from August 02, 2021 to October 18, 2022. He was Chairman & Lead Independent Director of Zymergen Inc. from April 13, 2021 to August 02, 2021. He was Lead Independent Director of Zymergen Inc. from January 21, 2020 to April 13, 2021. He was employed at Zymergen Inc. until October 18, 2022. He was Chairman of GRAIL, Inc. He was Chairman of the Board of Iridia, Inc. until September 2025. He was employed at Iridia, Inc. until September 2025. He was Independent Director of Dynamics Special Purpose Corp. He was named multiple times to the Deloitte & Touche Fast 50 and Fast 500 lists, as well as to the Forbes 25 Fastest-Growing Tech Companies (2007, 2009 and 2010), the Fortune 100 Fastest-Growing Companies (2010 and 2011) lists and recognition by MIT Technology Review as the World’s Smartest Company in 2014. He has M.S. summa cum laude in Industrial Engineering from Stanford University, B.S. in Industrial Engineering from Stanford University, B.A. in Economics from Claremont McKenna College.
Positions
- Company NameDenali Therapeutics Inc.Stock CodeDNLIPositionIndependent DirectorColleagues
- RJRyan J. WattsCo-Founder, President, CEO & Director
- JCJulian Charles BakerIndependent Chairperson
- AOAlexander O. SchuthCo-Founder, CFO, COO & Secretary
- DADana AndersenChief Technical and Manufacturing Officer
- JLJoe LewcockChief Scientific Officer
- CWChris WalshGeneral Counsel
- PSPeter S. KleinIndependent Director
- JEJennifer E. CookIndependent Director
